CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
Han Na Jang, Ye Seul Yang, Seong Ok Lee, Tae Jung Oh, Bo Kyung Koo, Hye Seung Jung
Endocrinol Metab. 2019;34(4):382-389.   Published online December 23, 2019
DOI: https://doi.org/10.3803/EnM.2019.34.4.382

Excel Download

Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)
Endocrinology and Metabolism. 2020;35(1):192   Crossref logo
Link1 Link2 Link3

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
Endocrinology and Metabolism. 2019;34(4):382   Crossref logo
Link1 Link2 Link3

Response: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang et al.)
Endocrinology and Metabolism. 2020;35(1):194   Crossref logo
Link1 Link2 Link3

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
Diabetes & Metabolism Journal. 2019;43:   Crossref logo
Link1 Link2 Link3

Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial
Diabetes, Obesity and Metabolism. 2013;15(9):826-832   Crossref logo
Link1

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes
Diabetic Medicine. 2015;33(4):497-505   Crossref logo
Link1 Link2 Link3

Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study
Diabetic Medicine. 2016;34(2):180-188   Crossref logo
Link1 Link2 Link3

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
Diabetes mellitus. 2014;17(4):108-119   Crossref logo
Link1 Link2

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
PLOS ONE. 2016;11(10):e0163350   Crossref logo
Link1

Efficacy and safety of switching from basal insulin to once-daily insulin degludec/insulin aspart in Japanese patients with inadequately controlled type 2 diabetes: A 4-week, randomized, open-label, treat-to-target study
Journal of Diabetes Investigation. 2017;9(3):567-572   Crossref logo
Link1 Link2